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background:  Statins protects mesenchymal stem cells (MSCs) against the harsh micro-environment and improve the efficacy of MSCs 
transplantation after acute myocardial infarction (AMI). However, the mechanism underlying this protective role of statins remains uncertain. Also, 
the transdifferentiation potential of MSCs in post-infarct hearts is still highly controversial. RhoA/ROCK pathway is involved in many aspects of 
damaged heart after AMI, and related to the “pleiotropic” effects of statins. This study aims to explore whether atorvastatin (ATV) facilitates MSCs 
survival and therapeutic efficacy via RhoA/ROCK/ERK1/2 inhibition, and investigate the transdifferentiation potential of MSCs in vivo.
methods and results: In animal experiment, female rats received myocardial injections of male rat MSCs 30 minutes after AMI. 4 weeks 
after AMI, ATV combined with MSCs treatment resulted in improved cardiac function and reduced infarction area. ATV facilitated MSCs survival as 
identified by increasing expression of Y chromosomal genes and more Y chromosome positive cells; but no markers of cardiac, vascular muscle or 
endothelial cells were observed in Y-chromosome positive cells. ATV inhibited inflammatory cytokines production both in hypoxia/serum deprivation 
(H/SD)-treated H9c2 cells and post-infarct hearts, accompanied by suppression of the ROCK and ERK activity. Geranylgeranyl pyrophosphate (GGPP) 
abrogated the effects of ATV in H9c2 cells under H/SD, while ROCK inhibitor Fasudil mimicked the benefits of ATV in post-infarct hearts.
Conclusions: ATV ameliorates the post-infarct micro-environment by RhoA/ROCK/ERK inhibition, and thus facilitates the survival of implanted 
MSCs and improves cardiac function. The transdifferentiation may be not responsible for the functional and structural recovery following MSCs 
transplantation.
